Trial Profile

The Prevention of Nephrotoxin-Induced Acute Kidney Injury Using Cilastatin (PONTiAK) Trial: A Phase 2B Vanguard Design, Randomized, Double-Blind, Placebo-Controlled Study

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Mar 2026 Accoring to Arch Biopartners media release, the Company is working to form a new U.S. arm of the PONTiAK trial to increase the clinical audience of cilastatin as a new treatment to prevent AKI and support patient enrollment. Trial is currently recruiting at hospital sites in both Calgary and Edmonton and plans to enroll a total of 698 patients in five hospital sites in Alberta.
22 Jul 2025 Accoring to Arch Biopartners media release, company announced that this trial has commenced patient recruitment at its primary clinical sites in Alberta, Canada
22 Jul 2025 Planned number of patients changed from 900 to 698, accoring to Arch Biopartners media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com